comparemela.com

Latest Breaking News On - Nicolas fellmann - Page 6 : comparemela.com

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities

09.04.2024 - PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ( Biophytis or the Company ), a clinical-stage biotechnology company specialized in the development of therapeutics for .

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

Biophytis / Key word(s): AGM/EGM/AGM/EGMRESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 04-Apr-2024 / 23:00 CET/CEST RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024All resolutions presented by the Company have been adopted Paris (France) and Cambridge (Massachusetts, USA), April 04, 2024.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.